Truist Securities Reiterates Buy Rating on Voyager Therapeutics (VYGR): 'evolving into a platform-agnostic, CNS disease focused biotech'

March 16, 2026 9:02 AM

Truist Securities analyst Joon Lee reiterated a Buy rating on Voyager Therapeutics (NASDAQ: VYGR)The analyst commented, "The highly anticipated Tau ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found